Profile data is unavailable for this security.
About the company
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
- Revenue in EUR (TTM)304.00k
- Net income in EUR-8.24m
- Incorporated2000
- Employees15.00
- Location4Sc AGFraunhoferstr. 22PLANEGG 82152GermanyDEU
- Phone+49 897007630
- Fax+49 8 970076329
- Websitehttps://www.4sc.de
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biofrontera AG | 28.63m | -8.61m | 22.33m | 91.00 | -- | 1.61 | -- | 0.7801 | -0.1383 | -0.1383 | 0.4748 | 0.2177 | 1.08 | 1.04 | 31.02 | 353,444.40 | -32.43 | -15.40 | -53.10 | -19.25 | 80.07 | 84.31 | -30.06 | -28.83 | 1.10 | 0.1264 | 0.0813 | -- | -10.59 | 16.44 | -215.26 | -- | 19.83 | -- |
| NanoRepro AG | 13.93m | -6.58m | 23.61m | 17.00 | -- | 0.5508 | -- | 1.69 | -0.5328 | -0.5328 | 1.14 | 3.32 | 0.2864 | 1.44 | 1.53 | 733,372.60 | -13.52 | 20.52 | -13.92 | 23.15 | 32.46 | 35.59 | -47.22 | 11.83 | 42.54 | -- | 0.00 | 31.99 | -76.35 | 87.53 | -112.53 | -- | 56.67 | -- |
| B.M.P. Pharma Trading AG | 1.64k | 1.57m | 32.19m | 45.00 | 20.40 | -- | 20.51 | 19,626.45 | 0.299 | 0.299 | 0.0003 | -- | -- | -- | -- | 36.44 | -- | 16.68 | -- | 17.58 | -46.34 | 0.2347 | 95,712.20 | 87,097.18 | -- | -493.86 | -- | -- | -96.34 | -61.60 | 75.39 | 43.01 | -- | -- |
| MediGene AG | -100.00bn | -100.00bn | 40.68m | 86.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -22.31 | -- | -25.28 | -- | 90.15 | -- | -123.17 | -- | -- | -- | -- | -80.69 | -4.89 | -94.20 | -- | -8.12 | -- |
| BRAIN Biotech AG | 55.23m | -8.40m | 61.17m | 311.00 | -- | 2.99 | -- | 1.11 | -0.3843 | -0.3843 | 2.53 | 0.9375 | 0.7778 | -- | -- | 167,351.50 | -11.67 | -10.71 | -15.18 | -14.46 | 56.12 | 56.16 | -15.01 | -17.47 | -- | -2.80 | 0.00 | -- | 11.79 | 14.12 | -25.63 | -- | 14.47 | -- |
| Apontis Pharma AG | 36.96m | -11.30m | 70.21m | 177.00 | -- | 2.27 | -- | 1.90 | -1.32 | -1.32 | 4.37 | 3.63 | 0.6302 | 3.09 | 23.11 | 208,835.00 | -19.27 | -- | -22.64 | -- | 62.68 | -- | -30.58 | -- | 2.58 | -- | 0.1659 | -- | -33.67 | -- | -520.38 | -- | -- | -- |
| 4Sc AG | 304.00k | -8.24m | 80.51m | 15.00 | -- | 15.82 | -- | 264.83 | -0.8144 | -0.8144 | 0.0301 | 0.4995 | 0.0236 | -- | 3.68 | 20,266.67 | -63.84 | -39.49 | -77.78 | -42.84 | 68.75 | 92.24 | -2,709.54 | -337.74 | -- | -- | 0.00 | -- | -30.28 | -40.78 | 42.64 | -- | -56.05 | -- |
| Haemato AG | 260.81m | 9.61m | 89.35m | 78.00 | 9.12 | 0.5859 | 8.30 | 0.3426 | 1.84 | 1.84 | 50.10 | 28.67 | 1.47 | 9.80 | 12.48 | 3,343,690.00 | 5.41 | 2.01 | 6.45 | 2.70 | 7.56 | 8.42 | 3.68 | 1.21 | 1.66 | -- | 0.0203 | 157.20 | -12.95 | -3.03 | 25.39 | 3.32 | -5.75 | -16.74 |
| Cantourage Group SE | -100.00bn | -100.00bn | 92.63m | 2.00 | -- | 2.09 | -- | -- | -- | -- | -- | 3.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Heidelberg Pharma AG | 9.05m | -18.28m | 140.28m | 98.00 | -- | 3.11 | -- | 15.50 | -0.3957 | -0.3957 | 0.196 | 0.968 | 0.1222 | 0.2187 | 11.87 | 95,273.69 | -24.68 | -43.91 | -33.18 | -64.34 | 79.75 | 52.13 | -201.94 | -206.24 | 2.22 | -- | 0.104 | -- | -46.75 | 21.87 | -3.27 | -- | -0.8341 | -- |
| PharmaSGP Holding SE | 97.55m | 14.99m | 280.80m | 85.00 | 18.75 | 7.67 | 11.53 | 2.88 | 1.25 | 1.25 | 8.13 | 3.05 | 0.7592 | 1.15 | 9.69 | 1,234,848.00 | 11.67 | 14.62 | 13.98 | 21.22 | 90.61 | 89.90 | 15.37 | 19.17 | 2.15 | 9.03 | 0.6809 | -- | 31.34 | 10.09 | 11.82 | 0.2886 | 14.67 | -- |
